Run new investigator-initiated clinical trials

Cancer Core Europe investigators initiating clinical trials will benefit from expedited contracting and the ability to quickly open trials across all members’ centers.


These harmonized procedures aim to facilitate Cancer Core Europe’s interactions with pharmaceutical industry partners. Our expertise in clinical biostatistics and methodology will support innovative next-generation clinical trial design.

Objectives

  • Profile patients according to molecular signatures and pathway alterations
  • Evaluate whether matching treatment to molecular abnormalities induces antitumor activity
  • Evaluate tumor heterogeneity, sensitivity, and resistance to treatment
  • Launch joint clinical trials
  • Follow-up patients using biopsies and liquid biopsies
  • Use innovative statistical designs in clinical trials with expert biostatistics support from within Cancer Core Europe